Neurocrine Biosciences | NBIX - Current Assets


Neurocrine Biosciences reported $2.01B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
ALKERMES USD 1.58B 57.83M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amgen USD 34.36B 598M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Exelixis USD 1.32B 70.8M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Prothena USD 273.86M 18.15M Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Repligen USD 1.24B 41.43M Sep/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Teva Pharmaceutical Industries USD 14.6B 842M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026